[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"helicobacter-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:helicobacter-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,69,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100237761","the-efficacy-of-the-7-days-tailored-therapy-as-the-1st-eradication-of-h-pylori-infection-100237761",false,"NCT02373280","The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori","Inclusion Criteria:\n\n* The patients who proved H. pylori infection following three methods\n\n  1. positive rapid urease test (CLOtest)\n  2. histologic evidence of H. pylori by modified Giemsa staining\n  3. positive Urea breath test\n* Male and female Korean Adult (Aged ≥ 18 years)\n\nExclusion Criteria:\n\n* Patients who received eradication therapy for H. pylori infection, previously\n* H. pylori eradication failure because of poor compliance\n* the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks\n* Advanced gastric cancer or other malignancy\n* Abnormal liver function or liver cirrhosis\n* Abnormal renal function or chronic kidney disease\n* Other severe concurrent diseases\n* Previous allergic reactions to the study drugs\n* Pregnant or lactating women",true,"ALL","18 Years","85 Years",{"count":21,"type":22},600,"ESTIMATED","INTERVENTIONAL",[25],"NA","To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.",[28],"Helicobacter Infection",[30,31,32],"Helicobacter pylori","tailored therapy","eradication","RECRUITING","2026-04-23",{"date":36,"type":37},"2026-04-24","ACTUAL",{"date":39,"type":4},"2014-08",{"date":41,"type":22},"2027-12",{"name":43,"class":44},"Seoul National University Bundang Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100584977","an-observational-study-for-gastric-cancer-in-carriers-of-high-risk-helicobacter-pylori-100584977","NCT06896370","An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori","Risk of Gastric Cancer in High-risk Carriers of Helicobacter Pylori: an Observational Cohort Study","Inclusion Criteria :\n\n1. Age ≥ 40 years, gender is not limited.\n2. Able and willing to provide informed consent and willing to undergo baseline and follow-up examinations.\n\nExclusion Criteria:\n\n1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.\n2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.\n3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.\n4. Pregnant or breastfeeding women.\n5. Other conditions that the investigator deems inappropriate for participation in the study.","40 Years",{"count":55,"type":22},3000,"OBSERVATIONAL","This study is intended to be a prospective observational cohort study. The incidence of gastric cancer and progression of gastric precancerous lesions will be compared between groups through prospective follow-up of a population with baseline negative gastric endoscopy, harboring high-risk Hp SNP subtypes and non-high-risk subtypes.",[59,28],"Gastric (Stomach) Cancer","2026-02-23",{"date":62,"type":37},"2026-02-25",{"date":64,"type":37},"2025-07-01",{"date":66,"type":22},"2035-12-31",{"name":68,"class":44},"Fudan University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100615538","phase-2-vonoprazan-vs-proton-pump-inhibitor-with-vitamin-d-or-probiotics-based-triple-therapy-for-eradication-of-helicobacter-pylori-infection-100615538","NCT07293910","Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","Inclusion Criteria:\n\n* Both male and female patients. • Patients ≥ 18 and \\\u003C80 years old.\n\nPatients with confirmed diagnosis of H. pylori infection using either stool antigen test, urea breath test or endoscopy.\n\nExclusion Criteria:\n\n* Pregnant or lactating patients. • Patients with inflammatory diseases. • Patients sensitive to any of the regimens' components. • Patients who had received a previous eradication therapy, recent use of antimicrobial agents, proton pump inhibitors, and H2 receptor blockers within 1 month.\n\nPatients with previous incidents of gastric or duodenal bleeding, gastric surgery or gastric malignancy.\n\n• Patients with active liver disease.\n\n• Patients with renal impairment.\n\n• Concurrent use of liver enzyme inducers, inhibitors or drugs with high plasma protein binding.","80 Years",{"count":78,"type":22},66,[80],"PHASE2","Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity. Its clinical significance is profound: it is classified as a Group 1 carcinogen by the World Health Organization and is a primary cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. The current first-line treatment, a PPI-based triple therapy (PPI + clarithromycin + amoxicillin), is experiencing a decline in efficacy (cure rates of 50-70%) due to widespread antibiotic resistance and compliance issues. To overcome this, newer agents like Vonoprazan Fumarate, a Potassium-Competitive Acid Blocker (P-CAB), are being adopted. Vonoprazan works by reversibly inhibiting the H+, K+ ATPase pump achieving stronger and longer-lasting acid suppression than PPIs because it does not require acid activation and is more stable in an acidic environment. In addition to pharmacological treatment, adjunctive therapies show promise. Vitamin D, acting through Vitamin D Receptor (VDR), assists in eradication by upregulating antimicrobial proteins like beta-defensin and cathelicidin, and its metabolite can cause bacterial cell lysis. Probiotics (primarily Lactobacillus and Bifidobacterium strains) enhance eradication rates by restricting bacterial growth, inhibiting adhesion, and exerting an anti-inflammatory effect through decreased interleukin-8 production. Finally, helicobacter pylori infection is marked by significant inflammation and oxidative stress. The bacterial protein TIP alpha induces high levels of the pro-inflammatory cytokine TNF alpha. Furthermore, the infection increases free radical production, leading to oxidative stress reflected by high levels of malondialdehyde. Systemic inflammation is also evident as helicobacter pylori infection is associated with significantly elevated serum C-reactive protein levels, which decrease upon successful eradication.\n\nAim of the work:\n\nThis study aims at evaluating the safety and efficacy of Vonoprazan vs Proton Pump Inhibitor with Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection.",[83,28,84,85],"HELICOBACTER PYLORI INFECTIONS","Helicobacter Pylori Gastrointestinal Tract Infection","Helicobacter Pylori Infected Patients",[87,88,89,90,91,92,93,94],"Helicobacter Pylori","Vonoprazan","Vitamin D","Probiotics","Lactobacillus","C-reactive protein","Tumor necrosis factor alpha","Malondialdehyde","2026-02-11",{"date":97,"type":37},"2026-02-13",{"date":99,"type":22},"2026-02-15",{"date":101,"type":22},"2026-12-20",{"name":103,"class":44},"Tanta University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100601798","phase-4-clinical-trial-to-evaluate-the-efficacy-of-probit-based-triple-therapy-for-helicobacter-pylori-eradication-100601798","NCT07115173","Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","A Single-Center, Single-Arm Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","Inclusion Criteria:\n\n1. Male or female, aged 19 to 75 years at consent.\n2. Confirmed H. pylori positive by urease breath or enzyme test.\n3. Require eradication therapy due to at least one condition: chronic atrophic gastritis, peptic ulcer, history of early gastric cancer or adenoma resection, functional dyspepsia, low-grade MALT lymphoma, idiopathic thrombocytopenic purpura, iron deficiency anemia, hyperplastic polyps, or family history of gastric cancer.\n4. Agree to use medically acceptable contraception during the trial (including medically sterile women such as menopausal, hysterectomy, tubal ligation, or bilateral oophorectomy).\n5. Provide voluntary written informed consent.\n\nExclusion Criteria:\n\n1. History of receiving H. pylori eradication therapy prior to study participation.\n2. Known hypersensitivity to the investigational product, penicillin-class antibiotics, or macrolide-class antibiotics.\n3. Current use of medications contraindicated with the investigational product or concomitant therapy.\n4. Abnormal laboratory values in blood chemistry tests as defined by the protocol.\n5. pregnant or nursing women","19 Years","75 Years",{"count":114,"type":22},103,[116],"PHASE4","This is a single-center, open-label, non-randomized, single-arm clinical study. Eligible participants who provide written informed consent will undergo screening based on inclusion\u002Fexclusion criteria. Enrolled subjects will receive the investigational treatment: Zastaprazan 20 mg (twice daily), clarithromycin 500 mg (twice daily), and amoxicillin 1000 mg (three times daily) for 14 days. Four to eight weeks after completing the therapy, participants will return for a urea breath test to assess H. pylori eradication. The study will also investigate the efficacy of this therapy in clarithromycin-resistant patients to indirectly assess the potential of a dual regimen using Zastaprazan and amoxicillin.",[28],"NOT_YET_RECRUITING","2025-08-11",{"date":122,"type":37},"2025-08-14",{"date":124,"type":22},"2025-12-01",{"date":126,"type":22},"2027-12-31",{"name":128,"class":44},"Samsung Medical Center"]